The first 5 pages, shown as text so search engines and readers can find this document.
Page 1
SCIENTIFIC OPINION
ADOPTED: dd mm 2018
doi:10.2903/j.efsa.2018.NNNN
www.efsa.europa.eu/efsajournal EFSA Journal 2018;volume(issue):NNNN
Update of the tolerable upper intake level for vitamin D for1
infants2
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA),3
Dominique Turck, Jean-Louis Bresson, Barbara Burlingame, Tara Dean,4
Susan Fairweather-Tait, Marina Heinonen, Karen Ildico Hirsch-Ernst, Inge5
Mangelsdorf, Harry J McArdle, Androniki Naska, Grażyna Nowicka, Kristina6
Pentieva, Yolanda Sanz, Alfonso Siani, Anders Sjödin, Martin Stern, Daniel7
Tomé, Henk Van Loveren, Marco Vinceti, Peter Willatts, Mary Fewtrell,8
Christel Lamberg-Allardt, Hildegard Przyrembel, Davide Arcella, Céline9
Dumas, Lucia Fabiani, Laura Martino, Daniela Tomcikova and Monika10
Neuhäuser-Berthold11
Abstract12
Following a request from the European Commission (EC), the Panel on Dietetic Products, Nutrition and13
Allergies (NDA) was asked to revise the Tolerable Upper Intake Level (UL) for vitamin D for infants14
(≤ 1 year) set in 2012. From its literature review, the Panel concluded that the available evidence on15
daily vitamin D intake and the risk of adverse health outcomes (hypercalciuria, hypercalcaemia,16
nephrocalcinosis and abnormal growth patterns) cannot be used alone for deriving the UL for infants.17
The Panel conducted a meta-regression analysis of collected data, to derive a dose-response18
relationship between daily supplemental intake of vitamin D and mean achieved serum 25(OH)D19
concentrations. Considering that a serum 25(OH)D concentration of 200 nmol/L or below is unlikely to20
pose a risk of adverse health outcomes in infants, the Panel estimated the percentage of infants21
reaching a concentration above this value at different intakes of vitamin D. Based on the overall22
evidence, the Panel kept the UL of 25 μg/day for infants aged up to 6 months, and set a UL of23
35 μg/day for infants 6–12 months. The Panel was also asked to advise on the safety of the24
consumption of infant formulae with an increased maximum vitamin D content of 3 μg/100 kcal25
(Commission Delegated Regulation (EU) 2016/127 repealing Directive 2006/141/EC in 2020). For26
infants aged up to 4 months, the intake assessment showed that the use of infant formulae containing27
vitamin D at 3 μg/100 kcal may lead some infants to receive an intake above the UL of 25 μg/day28
from formulae alone without considering vitamin D supplemental intake. For infants aged 4–29
12 months, the 95th percentile of vitamin D intake (high consumers) estimated from formulae and30
foods fortified or not with vitamin D does not exceed the ULs, without considering vitamin D31
supplemental intake.32
© 2018 European Food Safety Authority.
EFSA Journal published by John Wiley and Sons Ltd on33
behalf of European Food Safety Authority.34
Keywords: vitamin D, infants, adverse health outcomes, 25(OH)D, UL
, intake35
36
Requestor: European Commission37
Question number: EFSA-Q-2017-0020838
Correspondence: nda@efsa.europa.eu39
40
Page 2
UL of vitamin D for infants
www.efsa.europa.eu/efsajournal 2 EFSA Journal 2018;volume(issue):NNNN
Panel members: Jean-Louis Bresson, Barbara Burlingame, Tara Dean, Susan Fairweather-Tait,41
Marina Heinonen, Karen Ildico Hirsch-Ernst, Inge Mangelsdorf, Harry J McArdle, Androniki Naska,42
Monika Neuhäuser-Berthold, Grażyna Nowicka, Kristina Pentieva, Yolanda Sanz, Alfonso Siani, Anders43
Sjödin, Martin Stern, Daniel Tomé, Dominique Turck, Henk Van Loveren, Marco Vinceti and Peter44
Willatts.45
Acknowledgements: The Panel wishes to thank EFSA staff: Mathias Amundsen, Krizia Ferrini, Irene46
Muñoz Guajardo, Rita Sousa, Qingqing Sun and Ermolaos Ververis, for the support provided to this47
scientific opinion.48
Suggested citation: EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies),49
Turck D, Bresson J-L, Burlingame B, Dean T, Fairweather-Tait S, Heinonen M, Hirsch-Ernst KI,50
Mangelsdorf I, McArdle HJ, Naska A, Nowicka G, Pentieva K, Sanz Y, Siani A, Sjödin A, Stern M, Tomé51
D, Van Loveren H, Vinceti M, Willatts P, Fewtrell M, Lamberg-Allardt C, Przyrembel H, Arcella D,52
Dumas C, Fabiani L, Martino L, Tomcikova D, and Neuhäuser-Berthold M, 2017. 2018. Scientific53
opinion on the update of the tolerable upper intake level for vitamin D for infants. EFSA Journal54
2018;volume(issue):NNNN, 124 pp. doi:10.2903/j.efsa.2018.NNNN55
ISSN: 1831-473256
© 2018 European Food Safety Authority.
EFSA Journal published by John Wiley and Sons Ltd on57
behalf of European Food Safety Authority.58
This is an open access article under the terms of the Creative Commons Attribution-NoDerivs License,59
which permits use and distribution in any medium, provided the original work is properly cited and no60
modifications or adaptations are made.61
The EFSA Journal is a publication of the European Food
Safety Authority, an agency of the European Union.
62
Page 3
UL of vitamin D for infants
www.efsa.europa.eu/efsajournal 3 EFSA Journal 20YY;volume(issue):NNNN
Summary63
Following a request from the European Commission (EC), the Panel on Dietetic Products, Nutrition and64
Allergies (NDA) revised its Opinion of 2012 on the Tolerable Upper Intake Level (UL) for vitamin D,65
regarding the UL set for infants, i.e. aged less than 1 year. The UL is the maximum level of total66
chronic daily intake of a nutrient from all sources (i.e. foods, including supplements1) judged to be67
unlikely to pose a risk of adverse health effects in humans.68
This request arises in the context of Commission Delegated Regulation (EU) 2016/1272, which will69
repeal Directive 2006/141/EC3 from 2020, and increases the maximum allowed vitamin D content from70
2.5 to 3 μg/100 kcal for infant formulae (IF), i.e. to reach the same content as for follow-on formulae71
(FoF). In order to ensure the highest level of protection of infants consuming formulae, the72
Commission seeks EFSA's advice on the safety of the consumption of formulae containing73
3 μg/100 kcal of vitamin D by infants.74
The previous EFSA Opinion of 2012 on the revision of the ULs for vitamin D set by the Scientific75
Committee on Food (SCF) in 2003 concluded that there was a paucity of data on infants on which to76
base a no- or a lowest observed adverse effect level (NOAEL or LOAEL). Having considered in77
particular available evidence on ‘high’ vitamin D intake and absence of retarded growth or78
hypercalcaemia in infants, and as newer data from intervention studies in healthy infants had not79
become available since the previous risk assessment (SCF, 2003), the Panel decided in 2012 to retain80
the UL of 25 μg vitamin D/day previously derived for infants.81
Vitamin D is the generic term for ergocalciferol (vitamin D2) and cholecalciferol (vitamin D3), which are82
present in foods. Vitamin D3 is also synthesised endogenously in the skin following exposure to UV-B83
irradiation. While for other age groups beyond infancy, the synthesis of vitamin D3 in the skin during84
the summer months may be the main source of vitamin D and may fulfil the requirement, the Panel85
considers that this may not be the case for infants, who therefore have greater reliance on dietary86
intake. In the body, vitamin D is hydroxylated in the liver to 25-hydroxyvitamin D (25(OH)D), which is87
then hydroxylated to the biologically active metabolite 1,25-hydroxyvitamin D (1,25(OH)2D) primarily88
in the kidneys. Vitamin D, 25(OH)D and 1,25(OH)2D are transported in the blood mainly by the89
vitamin D-binding protein (DBP). The principal function of 1,25(OH)2D is to maintain calcium and90
phosphorus homeostasis.91
Serum 25(OH)D concentration is used as a biomarker of vitamin D intake in populations with low92
exposure to UV-B irradiation and of vitamin D status. All analytical methods available for its93
measurement have uncertainties, which could lead to over- or underestimations. Specifically in94
infants, some analytical methods may overestimate serum concentration of 25(OH)D, due to the fact95
that they detect also the C3-epimer of 25(OH)D, which may contribute up to about 40% of total96
25(OH)D during the first three months of life (contrary to older children and adults). However, the97
metabolic role of the C3-epimer is unclear.98
Vitamin D toxicity resulting from ‘long-term’ ingestion of ‘large’ doses of vitamin D is associated with99
an increase in the serum concentration of 25(OH)D and some other vitamin D metabolites but usually100
not of the active metabolite 1,25(OH)2D. Some hypotheses for mechanisms of toxicity have been101
proposed. The presence of elevated serum free 1,25(OH)2D concentration despite normal total102
1,25(OH)2D suggests that, in states of vitamin D toxicity, 1,25(OH)2D is displaced from DBP by103
25(OH)D or other metabolites, and that this could promote entry of free 1,25(OH)2D into target cells104
where it could stimulate gene transcription.105
Based on this and previous assessments, the Panel focussed on the following four adverse health106
outcomes: hypercalciuria, hypercalcaemia, ectopic calcification e.g. nephrocalcinosis, and abnormal107
1 Prophylactic administration of vitamin D in some countries may be considered as medication.
2 Commission Delegated Regulation (EU) 2016/127 of 25 September 2015 supplementing Regulation (EU) No 609/2013 of the
European Parliament and of the Council as regards the specific compositional and information requirements for infant formula
and follow-on formula and as regards requirements on information relating to infant and young child feeding, OJ L 25,
2.2.2016, p. 1
3 Commission Directive 2006/141/EC of 22 December 2006 on infant formulae and follow-on formulae and amending Directive
1999/21/EC, OJ L 401, 30.12.2006, p. 1
Page 4
UL of vitamin D for infants
www.efsa.europa.eu/efsajournal 4 EFSA Journal 20YY;volume(issue):NNNN
growth patterns. The Panel also collected data on serum 25(OH)D concentration in relation to108
vitamin D intake or adverse health outcomes, recognising that a ‘high’ concentration is not an adverse109
health outcome
per se, but can be considered as a surrogate endpoint.110
The Panel defined upfront the strategy and methodology to evaluate possible relationships between111
daily intake of vitamin D, i.e. D2 or D3 from all dietary sources including fortified foods and112
supplements, and adverse health outcomes or endpoints in infants. The Panel undertook a systematic113
literature search of trials and observational studies on full-term healthy infants, either breast-fed or114
fed with a standard IF or FoF, possibly receiving complementary foods, and appraised the risk of bias115
(RoB) of the studies.116
The Panel discussed the available evidence on the four adverse health outcomes from trials and117
observational studies. Although more data in infants are available since 2012, the Panel concludes118
that these data on daily vitamin D intake and adverse health outcomes (hypercalciuria,119
hypercalcaemia, nephrocalcinosis, and abnormal growth patterns) cannot be used alone for deriving120
the UL of vitamin D for infants. This is because of methodological limitations of the studies, including121
the use of unclear reference values for serum or urinary calcium in infants, and of single122
measurements that may not provide an indication of the risk of sustained elevated concentrations.123
Moreover, the studies showed inconsistent results, or absence of a dose-response relationship124
between vitamin D intake (or serum 25(OH)D concentration) and adverse health outcomes. The Panel125
notes the absence of data on the systematic administration of defined vitamin D doses above126
50 μg/day to healthy infants for ethical reasons. The level of daily vitamin D intake or serum 25(OH)D127
concentration that is associated with the occurrence of adverse health outcomes could not be128
determined on the basis of the available data and the Panel could not define a NOAEL for vitamin D129
intake. However, based on previous assessments and available data from infants, the Panel concludes130
that a serum 25(OH)D concentration of 200 nmol/L or below is unlikely to pose a risk of adverse131
health outcomes in healthy infants.132
Case reports described adverse health outcomes in infants associated with chronic daily administration133
of vitamin D doses of about 4.5 to 20 times the adequate intake (AI) of 10 μg/day set by EFSA in134
2016 for this age group; these outcomes were associated with elevated serum 25(OH)D135
concentrations. However, as these reports are based on incidental findings, they are not suitable to136
define a LOAEL for vitamin D in infants.137
The Panel conducted a meta-regression analysis of collected data to derive a dose-response138
relationship between daily supplemental intake of vitamin D and mean achieved serum 25(OH)D139
concentrations from data collected per arm of the trials selected through the literature search,140
adjusted for baseline serum 25(OH)D concentrations, age and duration of supplementation. This141
analysis was based on aggregated data from six trials with limited RoB, corresponding to 17 arms and142
58 time points, which used vitamin D from supplements and generally did not assess the intake of143
vitamin D from the diet. From this model, an empirical distribution of mean achieved serum 25(OH)D144
concentrations was generated from a large number of simulations. From this, a distribution of serum145
25(OH)D concentrations that may be achieved by individuals was then simulated, and the percentage146
of infants possibly reaching a concentration above 200 nmol/L was estimated for different vitamin D147
intakes.148
For infants aged up to 6 months, the Panel concludes that the available body of evidence supports149
keeping the previous UL of 25 μg/day. The Panel notes that predictions from the model support this150
conclusion. These predictions also show that, at a given intake of vitamin D, infants older than151
6 months achieve lower serum 25(OH)D concentration than infants younger than 6 months, which152
may be explained by the increase in body mass. Thus, for infants aged 6 to less than 12 months, the153
Panel considers that evidence from the predictions supports a UL of 35 μg/day.154
The Panel draws its conclusions on the UL for vitamin D from data mainly on vitamin D3, as the dose-155
response analysis to predict the percentage of individuals that would have serum 25(OH)D156
concentrations above 200 nmol/L included studies that used supplementation with vitamin D3.157
However, the updated UL of 25 and 35 μg/day applies both to vitamin D2 and D3.158
In order to characterise the risk of infants having an intake above the UL for vitamin D, the Panel159
assessed the daily vitamin D intake in Europe, considering in particular the consumption of formulae160
containing 3 μg/100 kcal of vitamin D. The intake assessment was conducted separately for infants161
Page 5
UL of vitamin D for infants
www.efsa.europa.eu/efsajournal 5 EFSA Journal 20YY;volume(issue):NNNN
aged up to 4 months, and for those aged 4 to less than 12 months, to account for the additional162
vitamin D intake in relation to the introduction of complementary feeding.163
Limited information was available to the Panel on the consumption of vitamin D-containing164
supplements from surveys in infants in Europe. In addition, the Panel notes that there are different165
national supplementation policies for vitamin D in infants in the EU and compliance with these policies166
may vary between countries. Furthermore, limited information was available on possible disparities167
between the labelled and the actual vitamin D content of a product (fortified foods or supplements).168
Thus, the Panel did not make any assumption regarding such disparities or regarding vitamin D169
supplementation in its intake assessment.170
For infants aged up to 4 months, according to calculations based on the maximal regulated vitamin D171
content in IF and the default ‘high’ IF consumptions set by the EFSA Scientific Committee in 2017172
(EFSA Scientific Committee et al., 2017a), the Panel concludes that, depending on the reference body173
weight used, age of the infants and energy content of formulae (without considering additional intake174
due to supplementation or possible disparities between the labelled and the actual composition of175
formulae):176
- the use of a maximum vitamin D content of 3 μg/100 kcal in IF (as per Delegated Regulation177
(EU) 2016/127) may lead some infants to consume amounts of vitamin D above the UL of178
25 μg/day from formulae alone;179
- the use of a maximum vitamin D content of 2.5 μg/100 kcal in IF (as per Directive180
2006/141/EC) does not result in intakes of vitamin D above the UL of 25 μg/day from181
formulae alone. The margin between the calculated intakes via formulae and the UL varies182
between 1 and 9 μg/day.183
For infants aged from 4 to 12 months, the intake assessment was conducted separately for consumers184
and non-consumers of IF and FoF. The intake assessment was done:185
- using food consumption data of infants from six surveys, most of them nationally186
representative of their respective EU countries;187
- and considering eight intake scenarios, based on the minimum or maximum amount of188
vitamin D in IF and FoF according to the two regulatory texts (Directive 2006/141/EC and189
Commission Delegated Regulation (EU) 2016/127) and based on the composition of foods190
fortified or not with vitamin D (without considering possible disparities between the labelled191
and the actual composition of foods), coming respectively from the EFSA Nutrient Composition192
Database, and from the Mintel Global New Products Database.193
These eight scenarios were assumed to describe situations that may occur on the EU market taking194
into account voluntarily fortified foods, different possible food patterns in infants but excluding the195
contribution from supplements, and the two extremes in the range of the vitamin D content in196
mandatorily fortified foods. They were not meant to reflect the fortification practices of the six EU197
countries that provided food consumption data. Means and 95th percentiles of estimated vitamin D198
intake were used to characterise the risk of exceeding the UL (without considering additional intake199
due to supplementation) for infants aged from 4 to 12 months:200
- For infants consuming neither formulae nor fortified foods and for those not consuming201
formulae but consuming fortified foods, the estimated means and 95th percentiles of vitamin D202
intake are below or at the AI of 10 μg/day.203
- For infants consuming IF or FoF containing the maximum amount of vitamin D of204
3 μg/100 kcal) but not consuming fortified foods, the estimated means and 95th percentiles of205
vitamin D intake are higher but do not exceed the UL of 35 μg/day (i.e. for infants 6–206
12 months). The margin between the estimated 95th percentile of vitamin D intake in formula207
consumers and the UL of 35 μg/day varies between about 15 and 22 μg/day. The margin208
calculated with the UL of 25 μg/day (i.e. for infants 4–6 months), varies between about 5 and209
12 μg/day.210
- With the additional intake of fortified foods, the estimated means and 95th percentiles of211
vitamin D intake are higher but do not exceed the UL of 35 μg/day (i.e. for infants 6–212
12 months). The margin between the estimated 95th percentile of vitamin D intake in formula213